Bovi-Shield GOLD® Approved for Single-dose BRSV Vaccination

NEW YORK (Sept. 24, 2008) — Up to 76 percent of U.S. beef and dairy herds have bovine respiratory syncytial virus (BRSV) present, which producers can now help prevent with a single dose of the industry’s most researched and best-selling viral vaccine – Bovi-Shield GOLD®.1,2

According to the University of Florida Institute of Food and Agricultural Sciences, BRSV outbreaks will likely result in 100 percent of the cattle in susceptible herds becoming infected, with 20 to 50 percent of animals showing clinical signs and a death loss up to 5 percent.1 With this USDA-approval, Bovi-Shield GOLD now helps provide convenient, industry-leading protection against BRSV, as well as infectious bovine rhinotracheitis (IBR), parainfluenza-3 (PI3), and bovine virus diarrhea (BVD) types 1 and 2.

“In addition to the convenience of a single-dose BRSV vaccination,” said Victor Cortese, DVM, PhD, DABVP, director of specialty veterinary operations for Pfizer Animal Health, “Bovi-Shield GOLD is now approved for both intramuscular and subcutaneous administration, giving producers additional flexibility in their management programs and helping beef producers meet beef quality assurance guidelines.”

The upgraded formulation of Bovi-Shield GOLD also includes a new virus to help prevent PI3 infections.

“PI3 by itself isn’t a severe threat to cattle health,” said Cortese, “but the virus can occur with other respiratory diseases like BRSV, IBR and BVD, and the combination of diseases can be very harmful to cattle.”

Cortese added that, based on extensive research, Pfizer Animal Health updated the PI3 strain in Bovi-Shield GOLD to ensure it helps provide the best protection possible following subcutaneous administration.

These new claims do not apply to Bovi-Shield GOLD® FP® reproductive vaccines.

The Bovi-Shield GOLD line and PregGuard® GOLD FP 10 are recommended for vaccination of healthy cows and heifers approximately 1 month prior to breeding. These products can also be administered to pregnant cattle provided they were vaccinated, according to label directions, with any Bovi-Shield GOLD FP or PregGuard GOLD FP vaccine prior to breeding initially and within 12 months thereafter. Failure to follow label directions may result in abortions. The Bovi-Shield GOLD line may be administered to calves nursing pregnant cows, provided their dams were vaccinated within the last 12 months as described above. Consistent with good vaccination practices, heifers should receive at least 2 vaccine doses, with the second dose administered approximately 30 days pre-breeding.

Pfizer Inc. (NYSE: PFE), the world’s largest research-based pharmaceutical company, is a world leader in discovering and developing innovative animal vaccines and prescription medicines. Pfizer Animal Health is dedicated to improving the safety, quality and productivity of the world’s food supply by enhancing the health of livestock and poultry; and in helping companion animals live longer and healthier lives. For additional information on Pfizer’s portfolio of animal products, visit

# # #

1 Richey E.J. Bovine Respiratory Syncytial Virus (BRSV) and Parainfluenza-3 (PI-3) University of Florida, Institute of Food and Agricultural Sciences Extension. Accessed Aug 27, 2008.

2 MDI MAT ending June 2008.

All brands are the property of Pfizer Inc., its affiliates and/or its licensors. ©2008 Pfizer Inc. All rights reserved. BSD08042

Pfizer Inc. • 150 East 42nd Street • New York, NY 10017

For further information, contact:

Rebecca Lambert

Pfizer Animal Health


[email protected]

Kenna Rathai



[email protected]